The choice of coronary revascularization method depending on comorbid pathology

Abstract

Coronary heart disease plays a leading role in global mortality statistics. Despite the obvious progress in the development of new drug regimens, surgical treatment remains an important component. The high prevalence and complexity of treatment of patients with CHD and comorbid pathology, especially diabetes mellitus and chronic kidney disease, make researchers think about proper approaches to therapy of such patients. The decision to perform revascularization is made in consultation with all Heart Team members, taking into account the results of the invasive study, the presence of complaints in the patient and his "response" to drug therapy. Percutaneous coronary interventions (PCI) are still statistically more likely to result in restenosis and repeat revascularizations than open surgery. Hybrid myocardial revascularization is an alternative method combining the advantages of coronary artery bypass and PCI and reducing the risks of both procedures adverse complications. The choice of the optimal strategy of surgical treatment in patients with comorbid pathology requires special attention.